AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.
Shares of AstraZeneca PLC AZN rallied 1.18% to £111.80 Monday, on what proved to be an all-around positive trading session ...
Invest Ontario is partnering with AstraZeneca (AZN) to expand the company’s global R&D hub in Mississauga. This C$820M investment underscores Ontario’s growing prominence in the life sciences ...
The institutional investor owned 10,908 shares of the company’s stock after selling 674 shares during the quarter. Mutual Advisors LLC’s holdings in AstraZeneca were worth $730,000 at the end ...
Understanding the enormous commercial potential of this market, the company continues to actively expand its portfolio of FDA-approved and experimental drugs. Overall, sales of AstraZeneca's ...
AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...
The positive recommendation from NICE for osimertinib was based on results from the ADAURA Phase III trial. In which, adjuvant treatment (after surgery) with osimertinib in patients with stage II ...
Through Alexion, which AstraZeneca acquired in 2021, the company will gain access to LogicBio’s technology platforms for the delivery and insertion of genes to address genetic diseases ...
AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, today announced a C$820 million (US$570m) investment in Canada, creating more than 700 high-skilled jobs ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...